PharmaTher enters North American deal with Craft Health
Toronto-based company becomes sole distributor of CraftMake pharmaceutical 3D printer, software and printable formulations in the U.S. and Canada
PharmaTher has become the exclusive North American distributor of the CraftMake pharmaceutical 3D printing platform under an agreement with Singapore-based Craft Health Pte. Ltd. The deal covers CraftMake printers, CraftControl software, CraftBlends formulations, consumables and service.
“This agreement is a defining step for PharmaTher,” said Fabio Chianelli, Chairman and Chief Executive Officer of PharmaTher. “We now hold exclusive North American rights to a GMP-ready pharmaceutical 3D printing platform, across every customer segment that matters.
“Each system we install is expected to generate recurring revenue and extend the reach of our product and partnership initiatives. It also secures the foundation of our Personaliz3d platform, which supports our proprietary personalized 503A peptide products, our FDA rare disease program and our national emergency and medical countermeasures initiatives, and it lets us offer CDMO and white-label services to other healthcare companies.”
Exclusivity applies to compounding pharmacies, telehealth companies, contract development and manufacturing organizations (CDMOs), hospitals, research and government institutions, and pharmaceutical and biotechnology firms.
PharmaTher envisages more than 10,000 possible placement sites, and plans initial orders for Q4 2026. It will provide installation, training, validation and service.
“North America is a key market for personalized medicine, and PharmaTher brings the pharmaceutical development, regulatory and commercial experience to build it,” said Dr. Wei Jiang Goh, Co-Founder and Chief Executive Officer of Craft Health. “We look forward to supporting PharmaTher as it brings CraftMake and complementary technologies to pharmacies, healthcare providers and researchers across North America.”
